Биология ва тиббиёт муаммолари 2025 №5 (165)

Тема статьи

СУРУНКАЛИ БУЙРАК КАСАЛЛИГИ ВА УНИ ЖАҲОНДА ТАРҚАЛИШИ (348-353)

Авторы

Гадаев Абдигаффор Гадаевич, Махмонов Лутфулла Сайдуллаевич

Учреждение

1 - Тошкент давлат тиббиёт университети, Ўзбекистон Республикаси, Тошкент ш.; 2 - Самарқанд давлат тиббиëт университети, Ўзбекистон Республикаси, Самарқанд ш.

Аннотация

Ушбу мақолада сурункали буйрак касаллигини жахонда тарқалиши бўйича хорижий адабиётлар тахлили келтирилган. Унда ушбу оғир асоратни бутун дунёда кенг тарқалганли кўрсатилиб лекин турли мамлакатлар ва худудларда бир биридан фарқ қилиши кўрсатилган. Сурункали буйрак касаллиги 1-5 босқичи 6908440 беморлар қатнашган 100 та тадқиқот асосида ўтқазилган мета тахлилда 13,4% ни ташкил этиши қайт этилган. Унинг 3-босқичи энг кўп учраб 7,6% га тенг бўлган. Бу рақамлар республикамиз худудлари бўйича хам мазкр оғир асоратни оғирлик даражалари бўйича ўрганиш мухим ахамиятга эга. Чунки олинган натижалар келажакда фаол даволаш усулларини режалаштириш имкониятини беради.

Ключевые слова

сурункали буйрак касаллигини, сурункали буйрак касалигининг босқичлари, хисобланган коптокчалар филтирацияси.

Литературы

1. Абдуллаев Д. Ш., Гадаев А. Г., Ризаев Ж. А. Матриксные металлопротеиназы у больных с болезнями пародонта и хронической сердечной недостаточностью //Stomatologiya. – 2017. – №. 2. – С. 104-106. 2. Арингазина А. М., Нарманова О. Ж., Нускабаева Г. О., Тагаева Ж. А., Мендыбаев Е. С. Хроническая болезнь почек: распространенность и факторы риска (обзор литературы) 3. Ризаев Ж. А., Гадаев А. Г., Абдувакилов Ж. У. Иммунологические аспекты патогенеза патологии пародонта у больных с хронической сердечной недостаточностью //Journal of biomedicine and practice. – 2016. – Т. 1. – №. 1. – С. 6-10. 4. Ризаев Ж. А., Гадаев А. Г., Абдуллаев Д. Ш. Параллели патогенеза заболеваний пародонта и хронической сердечной недостаточности //Dental Forum. – Общество с ограниченной ответственностью" Форум стоматологии", 2017. – №. 4. – С. 70-71. 5. Махмонов Л. С., Ризаев Ж. А., Гадаев А. Г. Helicobacter pylori ва уни темир ҳамда витамин в12 танқислиги камқонлиги юзага келишидаги аҳамияти. – 2021. 6. Benghanem G.M., Elseviers M., Zamd M., et al. Chronic kidney disease, hypertension, diabetes, and obesity in the adult population of Morocco: how to avoid ‘over’- and ‘under’-diagnosis of CKD // Kidney Int. - 2016. - Vol. 89. - Р. 1363–1371). 7. (Bikbov B.T., Tomilina N.A. Substitute therapy for treating terminal kidney failure in the Russian Federation in 1998–2013. A report issued basing on data provided by the Russian register of substitute kidney therapy. Part I. Nefrologiya i dializ, 2015, no. 3, 111 p.). 8. (Bowe B., Xie Y., Li T., Mokdad A.H. Changes in the US burden of chronic kidney disease from 2002 to 2016: an analysis of the global burden of disease study. JAMA Netw Open, 2018, vol. 2, no. 1 (7), pp. e184412. DOI: 10.1001/jamanetworkopen.2018.4412). 9. (Brück K., Jager K.J., Dounousi E., et al. Methodology used in studies reporting chronic kidney disease prevalence: a systematic literature review // Nephrol Dial Transplant. 2016. Vol. 31. Р. 680. 10. (Brück K., Stel V.S., Gambaro G., et al. CKD prevalence varies across the European general population // J Am Soc Nephrol. 2016. Vol. 27. Р. 2135–2147). 11. (CG73 Chronic kidney disease: full guideline 2008. The published full clinical guideline on Chronic kidney disease including recommendations and methods used. NICE NIfCE. Available at: http://guidance.nice.org.uk/CG73/Guidance/pdf/English (06.09.2019)). 12. Choukem S.-P., Nchifor P.K., Halle M.-P., Nebongo D.N., Mboue-Djieka Y., Kaze F.F., Monekosso G.L. Knowledge of physicians on chronic kidney disease and their attitudes towards referral, in two cities of Cameroon: a cross-sectional study. BMC Res. Notes, 2016, no. 9, pp. 29.DOI: 10.1186/s13104-016-1845-5; 13. (Chow K.M., Szeto C.C., Kwan B., Leung C.B., Li P.K. Public lacks knowledge on chronic kidney disease: Telephone survey. Hong Kong Med. J., 2014, vol. 20, no. 2, pp. 139–144. DOI: 10.12809/hkmj134134). 14. Clin J Am Soc Nephrol. 2015. Vol. 10. Р. 1488–1499). 15. (Drawz P.E., Archdeacon P., McDonald C.J., et al. CKD as a model for improving chronic disease care through electronic health records 16. (Ene-Iordache B., Perico N., Bikbov B., Carminati S., Remuzzi A., Perna A., Islam N., Flores Bravo R. [et al.]. Chronic kidney disease and cardiovascular risk in six regions of the world (ISN‐KDDC): A cross‐sectional study. Lancet Glob. Health, 2016, vol. 4, no. 5, pp. e307–e319. DOI: 10.1016/S2214-109X(16)00071-1). 17. Fraser S.D.S., Roderick P.J., Casey M., Taal M.W., Yuen H.M., Nutbeam D. Prevalence and associations of limited health literacy in chronic kidney disease: a systematic review. Nephrology Dialysis Transplantation, 2013, vol. 28, no. 1, pp. 129–137. DOI: 10.1093/ndt/gfs371). 18. (Gao S.W., Oliver D.K., Das N., Hurst F.P., Lentine K.L., Agodoa L.Y., Sawyers E.S., Abbott K.C. Assesment of Racial Disparities in chronic kidney disease stage 3 and 4 care in the department of defense health system. Clin. J. Am. Soc. Nephrol., 2008, vol. 3, no. 2, pp. 442–449. DOI: 10.2215/CJN.03940907). 19. (GBD 2016 Causes of Death Collaborators. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet, 2017, vol. 390, no. 10100, pp. 1151–1210. DOI: 10.1016/S0140-6736(17)32152-9) 20. (Gerasimova O.Yu., Semchenko L.N., Remenets S.S. Epidemiology of chronic kidney diseases and organization of medical aid provided for patients with chronic kidney failure (literature review) Yuzhnoural'skii meditsinskii zhurnal, 2016, no.4, pp. 4–9). 21. Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: Lancet, 2015, vol. 386, no. 9995, pp. 743–800. DOI: 10.1016/S0140-6736(15)60692-4). 22. (Hill N.R., Fatoba S.T., Oke J.L., Hirst J.A., O’Callaghan C.A., Lasserson D.S., Richard Hobbs F.D. Global prevalence of chronic kidney disease – A systematic review and Metaanalysis // PLoS One. - 2016. - Vol. 6. e0158765) 23. (Imtiaz S., Salman B., Qureshi R., Drohlia M.F., Ahmad A. A review of the epidemiology of chronic kidney disease in Pakistan: A global and regional perspective. Saudi J Kidney Dis Transpl, 2018, vol. 29, no.6, pp. 1441–1451. DOI: 10.4103/1319-2442.248307). 24. (Jack K.C. Ng., Li P.K.-T. Chronic kidney disease epidemic: How do we deal with it? Nephrology, vol. 23, no. 4, pp. 116–120. DOI: 10.1111/nep.13464). 25. (Jafar T.H., Ramakrishnan C., John O., Tewari A., Cobb B., Legido-Quigley H., Sungwon Y., Jha V. Access to CKD Care in Rural Communities of India: a qualitative study exploring the barriers and potential facilitators. BMC Nephrol, 2020, no. 21, pp. 26. DOI: 10.1186/s12882-020-1702-6). 26. (Kalantar-Zadeh K., Golan E., Shohat T., Streja E., Norris K.C., Kopple J.D. Survival disparities within American and Israeli dialysis populations: learning from similarities and distinctions across race and ethnicity. Semin Dial, 2010, vol. 23, no. 6, pp. 586–594. DOI: 10.1111/j.1525-139X.2010.00795.x). 27. (KDIGO Clinical Practice Guideline for Glomerulonephritis // Kidney International Supplements. – 2012. - Vol. 2. - Р. 259–274; 28. (Laster M., Shen J.I., Norris K.C. Kidney disease Among African Americans: A population perspective. Am J. Kidney Dis., 2018, vol. 72, no. 5 (1), pp. S3–S7. DOI: 10.1053/j.ajkd.2018.06.021; 29. (Mathur R., Dreyer G., Yaqoob M.M., Hull S.A. Ethnic differences in the progression of chronic kidney disease and risk of death in a UK diabetic population: an observational cohort study. BMJ Open, 2018, vol. 27, no. 8 (3), pp. e020145. DOI: 10.1136/bmjopen-2017-020145). 30. (Mills K.T., Xu Y., Zhang W., Bundy J.D., Chen C.-S., Kelly T.N., Chen J., He J. A systematic analysis of world-wide population-based data on the global burden of chronic kidney disease in 2010. Kidney Int, 2015, vol. 88, no. 5, pp. 950–957. DOI: 10.1038/ki.2015.230). 31. (Parving H.H., Brenner B.M., McMurray J.J.V, et al, for the ALTITUDE Investigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes // N Engl J Med. 2012. Vol.367. Р. 2204–2213). 32. Saran R., Robinson B., Abbott K.C., Agodoa L.Y.C., Bhave N., Bragg-Gresham J., Balkrishnan R., Dietrich X. [et al.]. 33. (The published full clinical guideline on Chronic kidney disease including recommendations and methods used. NICE NIfCE. Available at: http://guidance.nice.org.uk/CG73/Guidance/pdf/English (06.09.2019)). 34. US Renal Data System 2017 Annual Data Report: epidemiology of kidney disease in the United States. Am. J. Kidney Dis., 2018, vol. 71, no. 3 (1), pp. S1–S672. DOI: 10.1053/j.ajkd.2018.01.002). 35. (Verhave J.C., Troyanov S., Mongeau F., Fradette L., Bouchard J., Awadalla P., Madore F. Prevalence, awareness, and management of CKD and cardiovascular risk factors in publicly funded health care. Clin. J. Am. Soc. Nephrol., 2014, vol. 9, no. 4, pp. 713–719. DOI: 10.2215/CJN.06550613). 36. (WHO. International Classification of Diseases version 11.2016. http://www.who.int/classifications/icd/en/(accessed Oct 2, 2016)).